Top Markets
Coin of the day
BELLUS Health Inc. BELLUS Health Inc.

BELLUS Health Inc.

BLU
Rank in Stocks #6891
BELLUS Health Inc. is a biopharmaceutical firm in the clinical development... BELLUS Health Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to creating new therapeutic options for intractable chronic cough (RCC) and various other conditions characterized by heightened cough sensitivity. The company's primary investigational compound, BLU-5937, functions as a P2X3 receptor antagonist. This drug is currently progressing through Phase II clinical trials, where it is being assessed for its potential in treating both RCC and persistent itching. Founded in 1993, BELLUS Health Inc. is headquartered in Laval, Canada.
Share Price
$14.30
Last synced: 2023-06-29
Market Cap
$1.81B
Change (1 day)
-2.81%
Change (1 year)
0.00%
Country
CA
Trade BELLUS Health Inc. (BLU)

Category

P/B ratio for BELLUS Health Inc. (BLU)
P/B ratio as of 2026 TTM: 0
According to BELLUS Health Inc. latest financial reports and stock price the company's current price-to-book ratio (TTM) is 0. At the end of 2026 the company had a P/B ratio of 0.
P/B ratio history for BELLUS Health Inc. from 2026 to 2026
P/B ratio at the end of each year
Year P/B Ratio Change
Not enough data for the provided dates.
P/B ratio for similar companies or competitors
Company P/B Ratio P/B Ratio Difference Country
6.3419 -
US
6.2413 -
NL
2.5054 -
AU
3.7087 -
US
- -
CH